Braveheart Bio, Inc.
- Last sale
- Nov 12, 2026 · -1.61%
- Market cap
- $1.84B
- 89.87M shares
- Filings
- 53
—
—
—Q3 2026
—Q3 2026
—Q3 2026derived
—Q3 2026
—Q3 2026
- $1.84B
- —
- —
- 3.7×
- —
- —
FY2026 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Research And Development
No annual history for this metric yet.
| Period | Ended | Value | Kind | Source trail |
|---|
Pharmaceutical preparations
Braveheart Bio, Inc. is the 101st largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
HRMYHarmony Biosciences Holdings, Inc.$868.5M21.5%18.3%$2.0BAGIOAgios Pharmaceuticals, Inc.$54.0M48.0%764.0%$1.9BZBIOZenas BioPharma, Inc.$10.0M100.0%3,777.4%$1.9B
BRVEBraveheart Bio, Inc. (this company)———$1.8B
ZYMEZymeworks Inc.$106.0M38.9%76.6%$1.8BQUREuniQure N.V.$16.1M40.6%1,236.0%$1.7BSRPTSarepta Therapeutics, Inc.$2.2B15.6%32.5%$1.7BKLRAKailera Therapeutics, Inc.———$1.7BSTOKStoke Therapeutics, Inc.$184.4M404.5%3.7%$1.7BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Braveheart Bio, Inc. · CIK 2131524 · Engraved from SEC EDGAR